Objective: To study the efficiency and the mechanism of QI-LE polysaccharide (QI-LE), a new compoundextracted from one kind of Chinese herbs with antiplatelet activity, against tumor metastasis in mice. Methods: QI-LE...Objective: To study the efficiency and the mechanism of QI-LE polysaccharide (QI-LE), a new compoundextracted from one kind of Chinese herbs with antiplatelet activity, against tumor metastasis in mice. Methods: QI-LE was prepared by our Lab. C57BL/6 female micetransplanted with H22 liver cancer cells were administered with the agent. Then the tumor nodules, pulmonarymetastasis rate, and tumor cell proliferation activity were checked. Proliferation changes of tumor cells treated with different concentrations of QI-LE were also tested. Results: High and middle dosage of QI-LE could inhibit both the lymphatic and blood systemic tumor pulmonary metastases significantly, but not the tumor cell proliferation in vitroConclusion: QI-LE has antitumor metastasis activity, thus may be a new candidates for antitumor metastases agents.展开更多
基金This work was supported by the ScienceFoundation from Health Department of Shandong Province (No. 2001CAICDAI) and Chinese Medicine Administration Bureau of Shandong Province(No. 99-46).
文摘Objective: To study the efficiency and the mechanism of QI-LE polysaccharide (QI-LE), a new compoundextracted from one kind of Chinese herbs with antiplatelet activity, against tumor metastasis in mice. Methods: QI-LE was prepared by our Lab. C57BL/6 female micetransplanted with H22 liver cancer cells were administered with the agent. Then the tumor nodules, pulmonarymetastasis rate, and tumor cell proliferation activity were checked. Proliferation changes of tumor cells treated with different concentrations of QI-LE were also tested. Results: High and middle dosage of QI-LE could inhibit both the lymphatic and blood systemic tumor pulmonary metastases significantly, but not the tumor cell proliferation in vitroConclusion: QI-LE has antitumor metastasis activity, thus may be a new candidates for antitumor metastases agents.